Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Medical Institutions, Baltimore, Maryland, United States of America.
Asuragen Inc., Austin, Texas, United States of America.
PLoS One. 2014 Mar 25;9(3):e93102. doi: 10.1371/journal.pone.0093102. eCollection 2014.
Development of head and neck squamous cell carcinoma (HNSCC) is characterized by accumulation of mutations in several oncogenes and tumor suppressor genes. We have formerly described the mutation pattern of HNSCC and described NOTCH signaling pathway alterations. Given the complexity of the HNSCC, here we extend the previous study to understand the overall HNSCC mutation context and to discover additional genetic alterations. We performed high depth targeted exon sequencing of 51 highly actionable cancer-related genes with a high frequency of mutation across many cancer types, including head and neck. DNA from primary tumor tissues and matched normal tissues was analyzed for 37 HNSCC patients. We identified 26 non-synonymous or stop-gained mutations targeting 11 of 51 selected genes. These genes were mutated in 17 out of 37 (46%) studied HNSCC patients. Smokers harbored 3.2-fold more mutations than non-smokers. Importantly, TP53 was mutated in 30%, NOTCH1 in 8% and FGFR3 in 5% of HNSCC. HPV negative patients harbored 4-fold more TP53 mutations than HPV positive patients. These data confirm prior reports of the HNSCC mutational profile. Additionally, we detected mutations in two new genes, CEBPA and FES, which have not been previously reported in HNSCC. These data extend the spectrum of HNSCC mutations and define novel mutation targets in HNSCC carcinogenesis, especially for smokers and HNSCC without HPV infection.
头颈部鳞状细胞癌(HNSCC)的发展特点是几个癌基因和肿瘤抑制基因的突变积累。我们以前描述过 HNSCC 的突变模式,并描述了 NOTCH 信号通路的改变。鉴于 HNSCC 的复杂性,在这里我们扩展了以前的研究,以了解 HNSCC 的整体突变情况,并发现其他遗传改变。我们对 51 个具有高度可操作性的与癌症相关的基因进行了高深度靶向外显子测序,这些基因在许多癌症类型中包括头颈部癌症中具有较高的突变频率。对 37 例 HNSCC 患者的原发肿瘤组织和匹配的正常组织进行了 DNA 分析。我们鉴定出 26 个非同义或终止获得性突变,针对 51 个选定基因中的 11 个。这些基因在 37 例研究的 HNSCC 患者中的 17 例(46%)中发生突变。吸烟者的突变数量比非吸烟者多 3.2 倍。重要的是,TP53 在 30%的 HNSCC 中发生突变,NOTCH1 在 8%的 HNSCC 中发生突变,FGFR3 在 5%的 HNSCC 中发生突变。HPV 阴性患者的 TP53 突变数量是 HPV 阳性患者的 4 倍。这些数据证实了之前报道的 HNSCC 突变谱。此外,我们在两个新基因 CEBPA 和 FES 中检测到突变,这两个基因以前在 HNSCC 中没有报道过。这些数据扩展了 HNSCC 突变谱,并确定了 HNSCC 发生过程中的新突变靶点,特别是针对吸烟者和没有 HPV 感染的 HNSCC。